Inhibition of sPLA2 has been evaluated in a double-blind placebo-controlled clinical trial of an oral formulation of Varespladib (LY333013) in 251 active RA patients not responsive to concomitant disease modifying drugs (DMARDs). This evidence concerns the gene PLA2G2A and rheumatoid arthritis.